Multi-layered wound dressing and method of manufacture

Information

  • Patent Grant
  • 11559437
  • Patent Number
    11,559,437
  • Date Filed
    Tuesday, October 24, 2017
    7 years ago
  • Date Issued
    Tuesday, January 24, 2023
    2 years ago
Abstract
A multi-layered wound dressing including a fibrous absorbent layer for absorbing exudate from a wound site. The wound dressing also includes a support layer configured to reduce shrinkage of at least a portion of the wound dressing.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a U.S. national stage application of International Patent Application No. PCT/EP2017/077154, filed on Oct. 24, 2017, which claims priority to GB Application No. 1618298.2, filed Oct. 28, 2016, entitled MULTI-LAYERED WOUND DRESSING AND METHOD OF MANUFACTURE.


BACKGROUND
Field

The present invention relates to a multi-layered wound dressing and a method of manufacturing such a wound dressing. In particular, but not exclusively, embodiments of the present invention relate to a multi-layered wound dressing having a fibrous absorbent layer that can resist shrinkage even under extreme sterilisation methods and storage conditions, have improved aesthetics and mechanical strength and thereby increase consistency of product over its shelf life.


Description of the Related Art

Wound dressings can be formed with a liquid-impermeable top layer (outer layer, furthest from the wound), which prevents wound exudates striking through and leaking from the dressing. The top layer is often also gas permeable and liquid vapour permeable, to help minimise maceration to the wound.


In some known wound dressings, the liquid-impermeable top layer can be susceptible to wrinkling (wrinkling includes but is not limited to inconsistent appearance, crinkles, creases textured surface). Wrinkling may occur whilst the wound dressing is packaged in a sterile packaging, and may be due to shrinking of one or more wound dressing layers over time. This may be due to the type of packaging and sterilisation method chosen. It could be perceived by a medical practitioner that if wrinkling is present the product has been compromised. Thus, it may not be possible to determine whether the wound dressing is still suitable for use. Wrinkling of the top layer may also occur whilst the wound dressing is in use. A wrinkled wound dressing is also visually unappealing to a patient.


Wound dressings often require a product shelf life of as long as possible, typically 5 years, so it is desirable to produce a wound dressing in which the liquid impermeable top layer is not as likely to wrinkle, become inconsistent in appearance or change aesthetics over time.


EP 1,314,410 discloses a multi-layered wound dressing having top film layer, but does not disclose any way of reducing or preventing shrinkage or wrinkling of the dressing.


SUMMARY

According to a first aspect of the present invention there is provided a multi-layered wound dressing comprising:

    • a fibrous absorbent layer for absorbing exudate from a wound site; and
    • a support layer configured to reduce shrinkage of at least a portion of the wound dressing.


According to a second aspect of the present invention there is provided a method of manufacturing a multi-layered wound dressing, the method comprising:

    • forming a support layer;
    • forming a fibrous absorbent layer for absorbing exudate from a wound site; and
    • laminating the support layer and the absorbent layer together to form the wound dressing;
    • wherein the support layer is configured to reduce shrinkage of at least a portion of the wound dressing.


According to a third aspect of the present invention there is provided a method of treating a wound comprising placing a multi-layered wound dressing according to any embodiment disclosed herein over a wound.


According to a fourth aspect of the present invention there is provided a method of providing negative pressure wound therapy to a wound, the method comprising:

    • placing a multi-layered wound dressing according to any embodiment disclosed herein over a wound;
    • forming a fluid flow path between the wound dressing and a negative pressure source; and
    • operating the negative pressure source to provide negative pressure to the wound.


According to a fifth aspect of the present invention there is provided a method of operating a negative pressure wound system, the method comprising:

    • operating a negative pressure source fluidically connected to a multi-layered wound dressing according to any embodiment disclosed herein, the wound dressing configured to be positioned over a wound.


According to a sixth aspect of the present invention there is provided a negative pressure wound therapy kit comprising a multi-layered wound dressing according to any embodiment disclosed herein and a negative pressure source configured to be fluidically connected to the wound dressing.


According to another aspect there is provided a multi-layered wound dressing comprising:

    • a fibrous absorbent layer for absorbing exudate from a wound site; and
    • a support layer configured to reduce shrinkage of at least a portion of the wound dressing,


      wherein the support layer comprises a net, the net comprises a geometric structure having a plurality of substantially geometric apertures extending therethrough; and


      the geometric structure comprises a plurality of bosses substantially evenly spaced and joined by polymer strands to form the substantially geometric apertures between the polymer strands.


According to another aspect there is provided a multi-layered wound dressing comprising:

    • a fibrous absorbent layer for absorbing exudate from a wound site; and
    • a support layer configured to reduce shrinkage of at least a portion of the wound dressing,


      wherein the net is formed from high density polyethylene.


According to another aspect there is provided a multi-layered wound dressing comprising:

    • a fibrous absorbent layer for absorbing exudate from a wound site; and
    • a support layer configured to reduce shrinkage of at least a portion of the wound dressing,


      wherein the support layer has a tensile strength from 0.05 to 0.06 Nm.


According to another aspect there is provided a multi-layered wound dressing comprising:

    • a fibrous absorbent layer for absorbing exudate from a wound site; and
    • a support layer configured to reduce shrinkage of at least a portion of the wound dressing,


      wherein the support layer is bonded to fibres in a top surface of the absorbent layer,


      the support layer further comprises a bonding layer, wherein the support layer is heat laminated to the fibres in the absorbent layer via the bonding layer; and


      wherein the bonding layer comprises a low melting point ethylene-vinyl acetate adhesive.


Certain embodiments of the invention provide the advantage that at least part of the wound dressing is less likely to shrink over time compared to known wound dressings.


Certain aspects of the invention provide a wound dressing in which wrinkling in a layer or layers of a wound dressing, e.g. a liquid impermeable film layer is prevented or reduced.





BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the invention are further described hereinafter with reference to the accompanying drawings, in which:



FIG. 1 is a schematic diagram of a section of an example of a wound dressing;



FIG. 2 is a schematic diagram of an example of a support layer;



FIG. 3A is a schematic diagram of a section of another example of a wound dressing;



FIG. 3B is a perspective view of the wound dressing of FIG. 3A;



FIG. 4 is a flow diagram of an example of a method of manufacturing the wound dressing of FIG. 3A;



FIG. 5 is a schematic diagram of a further example of a wound dressing; and



FIG. 6 is a schematic diagram of a yet further example of a wound dressing.



FIG. 7 is a schematic diagram of an example of a negative pressure wound therapy system.





In the drawings like reference numerals refer to like parts.



FIG. 1 shows an example of a multi-layer wound dressing 100. The wound dressing 100 includes a liquid impermeable film layer 102 located at the top of the wound dressing 100. In use, the film layer 102 is the top layer of the wound dressing 100, most distal from a wound site.


The film layer 102 is also gas and vapour permeable to allow for evaporation of fluid or wound exudate from the wound dressing 100, and help prevent maceration of the wound. In this example, the film layer 102 is formed from a polyurethane blend, though other suitable materials may include other polymeric materials, for example polyethylene, or polypropylene.


An absorbent layer 108 underlies the film layer 102. The absorbent layer 108 has a fibrous structure for absorbing exudate from a wound site. In this example, the absorbent layer 108 includes superabsorbent fibres. The absorbent layer 108 also includes other fibres. In this example, the absorbent layer includes superabsorbent fibres, viscose fibres and polyester fibres.


In this example, the absorbent layer 108 includes around 40% superabsorbent fibres, 40% viscose fibres, and 20% polyester fibres. In other examples, the absorbent layer may include around 0-50% superabsorbent fibres, 0-100% viscose fibres and 0-50% polyester fibres. Suitable superabsorbent fibres include crosslinked acrylate copolymer fibres that are partially neutralized to sodium salt however other superabsorbent fibres are available. The absorbent layer 108 may be manufactured using a needling process in which the fibres are mechanically tangled together.


In other examples, the absorbent layer may include other ratios of superabsorbent, viscose and polyester fibres. For example, the absorbent layer may include around 50% superabsorbent fibres, 35% viscose fibres and 20% polyester fibres. Alternatively, the absorbent layer may include 40% superabsorbent fibres and 60% viscose fibres.


The film layer 102 is located over the absorbent layer 108 so that wound exudate collected in the absorbent layer 108 can evaporate out of the wound dressing 100 through the film layer 102.


A support layer 106 is located between the film layer 102 and the absorbent layer 108. The support layer 106 helps to reinforce the structure of the absorbent layer 108 and thereby reduce shrinkage of the wound dressing 100. The support layer 102 also helps to provide extra mechanical strength to the film layer 102 to reduce or prevent wrinkling of the film layer 102 over time. The mechanical strength also reduces the chance of the dressing deforming or rolling up causing a pressure point.


Aptly, the support layer 106 is configured to have a tensile strength from 0.05 to 0.06 Nm to provide mechanical strength to the surrounding layers (e.g. the film layer 102 and the absorbent layer 108) without compromising the flexibility of the wound dressing 100. The support layer 106 may have a thickness of from 50 to 150 μm. Aptly, the support layer 106 may have a thickness of around 100 to 110 μm.


Referring to FIG. 2, the support layer 106 includes a net 200 configured to reduce shrinkage of the wound dressing 100. Aptly, the net 200 is configured to reduce shrinkage of the absorbent layer 108 and/or the film layer 102 to help reduce wrinkling of the film layer 102.


In this example, the net 200 has a substantially hexagonal (or honeycomb) structure 204 including a plurality of substantially triangular shaped apertures 202 extending therethrough.


The hexagonal structure 204 is formed from a plurality of dots (or bosses) 206 joined by polymer strands 208. The dots 206 are substantially evenly spaced with respect to each other. Each dot forms a vertex of the hexagonal pattern in the structure 204. Each dot 206 is joined to six surrounding dots 206 by polymer strands 208. That is, six polymer strands 208 extend from each dot 206 and each connect to a respective surrounding dot 206 to form the hexagonal structure 204 having triangular shaped apertures 202 between the polymer strands 208.


Each of the triangular shaped apertures 202 may have an area A of from 0.005 to 0.32 mm2. This allows liquid vapour from a wound to pass freely through the apertures, whilst still providing sufficient strength to the support layer 106.


It can also be said that the structure 204 is a structure comprising a plurality of strands or struts that are joined to form a plurality of triangles. In this example the triangles tessellate in rows. It will be appreciated that the strands or struts may be arranged in other formations, for example squares, diamonds or rectangles with different geometries and therefore differing open areas.


In this example, the support layer 106 is located directly adjacent the absorbent layer 108. As such, the support layer 106 can effectively provide additional mechanical strength to fibres in the top surface of the absorbent layer 108. This can help prevent movement of the fibres and reduce shrinking of the absorbent layer 108.


Aptly, the support layer 106 is bonded to the fibres in the top surface of the absorbent layer 108. This can help to lock the fibres in position and prevent or reduce any movement. In this example, the support layer 106 further includes a bonding layer for heat laminating the net 200 to the absorbent layer 108. The support layer 106 is thus heat laminated to fibres in the absorbent layer 108 via the bonding layer.


The bonding layer contained within the net has a lower melting temperature than the net 200 so that the support layer 106 can be heat laminated to the absorbent layer 108 whilst maintaining the structure of the net 200. The bonding layer can be formed from a low melting point polymer, for example a low melting point ethylene-vinyl acetate, whilst the net 200 may be formed from a high density polyethylene, which melts at a higher temperature than the bonding layer. Other polymers having a lower melting point than the net 200 may also be suitable. For example the bonding layer may be a separate layer or alternatively include an ethylene-acrylate or thermoplastic polyurethane based adhesive.


The net 200 and the bonding layer can be coextruded to form the support layer 106. Aptly, the bonding layer is extruded with a similar structural shape to the net 200, so that the apertures 202 in the net 200 are not obstructed by the bonding layer. This helps to ensure that exudate the absorbent layer 108 can pass through the support layer and evaporate out of the wound dressing 100 through the film layer 102.



FIG. 3 illustrates another example of a multi-layered wound dressing 300. The wound dressing 300 includes a film layer 302, support layer 306 and absorbent layer 308, the same as the film layer 102, support layer 106 and absorbent layer 108 described in relation to FIG. 1.


The wound dressing 300 also includes a first adhesive layer 304, located between the film layer 302 and the support layer 306, for attaching the film layer 302 to the support layer 306. The first adhesive layer 304 is a hot melt adhesive applied to a wound facing side (underside) of the film layer 302. Aptly, the first adhesive layer 304 is pattern coated onto the film layer 302, to include holes, so that gas and liquid vapour can pass through holes in the first adhesive layer 304. In other examples the film layer 302 may be laminated (e.g. heat laminated) directly onto the support layer 306 without the need for an adhesive layer 304 in between.


In this example, the wound dressing 300 also includes a foam layer 312, which is a fluid transport layer. The foam layer 312 is located under the absorbent layer 306. The foam layer 312 acts to draw fluid away from a wound site and transport the fluid to the absorbent layer 308. The foam layer may be formed from an open cell polyurethane foam and other options are available, as will be recognised by those skilled in the art.


An adhesive web layer 310 is located between the foam layer 312 and the absorbent layer 308 to adhere the foam layer 312 to the absorbent layer 308. The adhesive web layer may be formed from bicomponent polypropylene/polyethylene fibres. Such bicomponent fibres are known in the art, so for brevity will not be discussed in detail. The adhesive web layer 310 includes a plurality of apertures extending therethrough to allow for passage of exudate from the foam layer 312 to the absorbent layer 108.


The wound dressing 300 also includes a wound contact layer 320, which includes a perforated film 316. The perforated film 316 is located under the foam layer 312 and helps to prevent the wound dressing 300 from attaching to the wound as the wound heals. For example, where the wound dressing 300 includes the foam layer 312, the perforated film 316 can prevent new tissue from growing into cells of the foam layer 312. In other examples, the foam layer 312 may not be present and the perforated film 316 can help prevent fibres of the absorbent layer 308 from becoming embedded in the wound. Perforations in the perforated film 316 are aptly substantially uniformly distributed and are of suitable size to allow passage of exudate into the wound dressing 300, e.g. with holes having a diameter of 1-2.5 mm. The perforated film 316 is aptly formed from polyurethane.


The wound contact layer 320 may also include an adhesive 318 located under the perforated film 316 (i.e. on the wound facing side of the perforated film 316) for adhering the wound dressing 300 to the skin. In this case the adhesive is silicone 318 and is aptly spread onto the underside of the perforated film with a coat weight of around 30-200 g/m2. In some other examples, an additional attachment element, for example bandages, strips of tape, or compression bandages may be used to secure the wound dressing 300 to the patient.


The top side of the perforated film 316 (i.e. the side distal from the wound) may be coated with a further adhesive layer 314. The further adhesive layer 314 adheres the wound contact layer 320 to the foam layer 312. Aptly, the further adhesive layer 314 may be an acrylic adhesive, though other suitable adhesives may also be used. In other examples the wound contact layer 320 may be laminated (e.g. heat laminated) directly to the foam layer 312, without the need for the further adhesive layer 314 in between.



FIG. 4 illustrates an example of a method of manufacturing the wound dressing 300. The method is not limited to the steps shown and, as described above, may include additional steps. The method also is not limited to the order shown in FIG. 4. As will be appreciated by those skilled in the art, several of the method steps shown may be performed in a different order. In some embodiments, the wound dressing 300 is manufactured by forming each of the layers, and assembling the layers in the correct order, before heat laminating them together.


The film layer 302 may be formed by extrusion. At step 401, the first adhesive layer 304 is applied to the film layer. Aptly, the first adhesive layer 304 is pattern coated onto the underside of the extruded film layer 302.


At step 402 the support layer 306 and the absorbent layer 308 are heat laminated together to form a single piece. At step 403 the film layer 302 and first adhesive layer 304 are heat laminated to the support layer 306 on the top side of the single piece and the adhesive web layer 310 and foam layer 312 are heat laminated to the absorbent layer 308. Whilst the layers have been described as being heat laminated together in a specific order, the layers may be separately laminated together or laminated together all at the same time.


At step 404 the wound contact layer 320 is formed by coating one side of a film layer with the silicone adhesive layer 314, and coating the other side of the film layer with a further adhesive layer 314. The film layer is then perforated at step 405 (e.g. by needle punching), to form the wound contact layer 320 including the perforated film 316, the silicone adhesive layer 314 for contacting the wound and the further adhesive layer 314. Alternatively, the film layer may be perforated before adding the further adhesive layer 314.


The wound contact layer may then be laminated (e.g. with heat, ultrasonic and/or radio frequency welding) to the underside of the foam layer 312 to form the wound dressing 300, as shown at step 406.


At step 407 a removable cover may be applied to the underside of the silicone adhesive layer 318. This cover can be removed before the wound dressing 300 is applied to a patient.


At step 408 the wound dressing 300 may be cut into separate wound dressing pieces, each suitably sized for an intended application.


In another example, as shown in FIG. 5, the film layer 502 may have a larger surface area than the remainder of the wound dressing 500 so that it extends further outwardly than the other layers of the wound dressing. The wound-facing (underside) of the film layer may be coated with a pressure sensitive adhesive 504 (or other suitable adhesive) for sticking the dressing to the patient around the wound periphery. The pressure sensitive adhesive 504 may also adhere the film layer 502 to the support layer 506 of the wound dressing 500. The wound dressing may also include an absorbent layer 508, adhesive web layer 510, foam layer 512, further adhesive layer 514 and wound contact layer 520. Each of the layers in this example may be similar to corresponding layers described above in relation to FIGS. 3A and 3B, so for brevity will not be described again in detail.


In this example, the wound dressing may be manufactured following steps 401 to 407 described above. However, instead of cutting the dressing to size (step 408) each wound dressing may be made individually with each layer cut or formed to the desired size prior to laminating all the layers together so that the final wound dressing has a film layer larger than the other layers.


In a further example, as shown in FIG. 6, both the wound contact layer 620 and the film layer 602 may extend beyond the remaining layers of the wound dressing 600. The wound contact layer 620 and the film layer may be adhered together around the periphery (e.g. via an adhesive layer 604), so that the remaining layers of the wound dressing are sandwiched between the wound contact layer 620 and the film layer 602. In other words the support layer 606, the absorbent layer 608, the adhesive web layer 610, and the foam layer 612 may be sealed within a cavity 622 between the film layer 602 and the wound contact layer 620. In this example, a further adhesive layer 614 adheres the foam layer 612 to the wound contact layer 620, though in other examples the further adhesive layer 614 may not be required. Each of the layers in this example may be similar to corresponding layers described above in relation to FIGS. 3A and 3B, so for brevity will not be described again in detail.


The wound dressing 600 in this example may be manufactured similarly to the wound dressing 300, as described above, but with the film layer 602 and the wound contact layer 620 being laminated together around the periphery (e.g. via the adhesive layer 604) to sandwich the remaining layers between the film layer 602 and the wound contact layer 620. Alternatively, the film layer 602 may be directly laminated around the periphery (e.g. heat laminated) to the wound contact layer 620, without the need for the additional adhesive layer 604.


Although the wound dressings 300, 500, 600 have been described having several adhesive layers, one or more of these layers may not be present. For example, the perforated film itself may be formed from a hot melt adhesive material so that it can be directly heat laminated onto the foam layer, in which case the further adhesive layer may not be needed. In another example, the adhesive web layer may not be present if the foam and absorbent layers are adhered in another way. For example, the foam and absorbent layers may be directly chemically bonded together. Similarly, the first adhesive layer may not be needed. For example if the support layer includes an adhesive material, or if the film layer itself is formed from a hot melt adhesive then the film layer and the support layer may be directly adhered together.


In another example, the wound dressing may be provided without the foam layer. The foam layer helps to transport exudate away from the wound. However in some cases, and depending on the severity of a wound, the absorbent layer may sufficiently draw exudate from the wound without the need for the foam layer.


Although in the examples described above, the support layer is heat laminated to the absorbent layer via a bonding layer, other laminating techniques may be suitable. For example, the bonding layer may include a pressure sensitive adhesive. In this case, heat may not be required to laminate the support layer and adhesive layer together.


Although in the example described above, the net layer has been described as having a substantially hexagonal shaped structure, other geometric structures may also be suitable.


With other geometric structures, the apertures may also have different geometric shapes.


In another example, the wound dressing may include more than one support layer to provide support to other layers in the wound dressing. For example a first support layer may be located between the liquid impermeable film layer and the absorbent layer, and a further support layer may be located between the absorbent layer and the fluid transport layer (foam layer). This may help to support the absorbent layer from both sides to further reduce shrinking of the absorbent layer.


Any of the examples described herein may be adapted for use with a negative pressure system (sometimes referred to as a reduced pressure system) including a source of negative pressure, such as a negative pressure pump. For example, the film layer may include a negative pressure interface, such as a port, to which a negative pressure supply tube may be connected. The supply tube may be connected to a negative pressure source so that, in use, the negative pressure source applies a negative pressure to the wound dressing between the film layer and the wound to help draw wound exudate away from the wound and into the absorbent layer of the dressing.



FIG. 7 illustrates an example of a negative pressure wound therapy system 700. The system includes a wound cavity 710 covered by a wound dressing 720, which can be a dressing according to any of the examples described herein. The dressing 720 can be positioned inside the wound cavity 710 and further seal the wound cavity so that negative pressure can be maintained in the wound cavity. For example, a film layer of the wound dressing 720 can provide substantially fluid impermeable seal over the wound cavity 710. A single or multi lumen tube or conduit 740 connects the wound dressing 720 with a negative pressure device 750 configured to supply reduced pressure. The negative pressure device 750 includes a negative pressure source. The negative pressure device 750 can be a canisterless device (meaning that exudate is collected in the wound dressing and/or is transferred via the tube 740 for collection to another location). In some embodiments, the negative pressure device 750 can be configured to include or support a canister. Additionally, in any of the embodiments disclosed herein, the negative pressure device 750 can be fully or partially embedded in, mounted to, or supported by the wound dressing 720.


The conduit 740 can be any suitable article configured to provide at least a substantially sealed fluid flow path or pathway between the negative pressure device 750 and the wound cavity 710 so as to supply reduced pressure to the wound cavity. The conduit 740 can be formed from polyurethane, PVC, nylon, polyethylene, silicone, or any other suitable rigid or flexible material. In some embodiments, the wound dressing 720 can have a port configured to receive an end of the conduit 740. For example, a port can include a hole in the film layer. In some embodiments, the conduit 740 can otherwise pass through and/or under a film layer of the wound dressing 720 to supply reduced pressure to the wound cavity 710 so as to maintain a desired level of reduced pressure in the wound cavity. In some embodiments, at least a part of the conduit 740 is integral with or attached to the wound dressing 720.


In use, the wound dressing, such as the wound dressing 100, 300, 500, or 600, is applied to a wound site with the wound contact layer 320 contacting the wound. Exudate from the wound may pass through the perforated film 116 and into the foam layer 312, which acts to transport wound exudate away from the wound into the absorbent layer 308. Wound exudate collected in the absorbent layer 308 can evaporate from the wound dressing 300 through the vapour permeable film layer 302.


The support layer helps to provide mechanical strength to the absorbent layer, which may swell when it is wet and may shrink as it dries. The support layer can help to minimise movement of fibres in the absorbent layer at least on the side distal from the wound and thus helps to prevent shrinking of the wound dressing, particularly in this region. Minimising shrinking of the wound dressing in this way can in turn can help to prevent wrinkling of the film layer. It also reduced the chance of the dressing rolling/folding up under secondary retention.


As the wound dressing becomes exposed to moisture (either from the wound or the surrounding atmosphere), it may swell or expand causing increased wrinkling of the film layer. Having the support layer adhered to the film layer can help to provide support to the film layer and resist wrinkling of the film layer by providing additional mechanical strength to the film layer.


The above described wound dressings are less likely to exhibit shrinking whilst stored in sterile packaging than previously known wound dressings. Thus, wrinkling of the film layer on the outside of the wound dressing can be prevented or reduced. A medical practitioner is therefore less likely to disregard a wound dressing that is still within its recommended shelf life, sterile and suitable for use, purely because of visual appearance of the film layer.


The hexagonal and/or triangular shape of the net structure of the support layer helps to provide mechanical strength and can be particularly effective at resisting against shrinkage of surrounding wound dressing layers.


Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of them mean “including but not limited to”, and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps. Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.


Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.


The reader's attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.

Claims
  • 1. A multi-layered wound dressing comprising: a fibrous absorbent layer for absorbing exudate from a wound site;a support layer configured to reduce shrinkage of at least a portion of the multi-layered wound dressing; anda liquid impermeable film layer,wherein the support layer is located between the absorbent layer and the film layer, andwherein the support layer has a tensile strength from 0.05 to 0.06 Nm.
  • 2. A multi-layered wound dressing according to claim 1, wherein the support layer comprises a net.
  • 3. A multi-layered wound dressing according to claim 2, wherein the net comprises a geometric structure having a plurality of substantially geometric apertures extending therethrough.
  • 4. A multi-layered wound dressing according to claim 3, wherein the geometric structure comprises a plurality of bosses substantially evenly spaced and joined by polymer strands to form the plurality of substantially geometric apertures between the polymer strands.
  • 5. A multi-layered wound dressing according to claim 4, wherein the geometric structure of the net comprises a hexagonal structure, and wherein the plurality of substantially geometric apertures have triangular shape.
  • 6. A multi-layered wound dressing according to claim 5, wherein a boss of the plurality of bosses form a vertex of the hexagonal structure with polymer strands extending from the boss and connecting the boss to neighboring bosses, and wherein the plurality of substantially geometric apertures are formed between neighboring polymer strands.
  • 7. A multi-layered wound dressing according to claim 2, wherein the net is formed from high density polyethylene.
  • 8. A multi-layered wound dressing according to claim 3, wherein the plurality of substantially geometric apertures have an area from 0.005 to 0.32 mm2.
  • 9. A multi-layered wound dressing according to claim 1, wherein the support layer has a thickness of from 50 to 150 μm.
  • 10. A multi-layered wound dressing according to claim 1, wherein the support layer is located directly adjacent the absorbent layer.
  • 11. A multi-layered wound dressing according to claim 1, wherein the support layer is bonded to fibres in a top surface of the absorbent layer.
  • 12. A multi-layered wound dressing according to claim 11, wherein the support layer further comprises a bonding layer, wherein the support layer is heat laminated to the fibres in the absorbent layer via the bonding layer.
  • 13. A multi-layered wound dressing according to claim 12, wherein the bonding layer comprises a low melting point ethylene-vinyl acetate adhesive, and wherein the support layer comprises a net formed from a material with a higher melting temperature than that of the bonding layer.
  • 14. A multi-layered wound dressing according to claim 1, further comprising an adhesive layer attaching the film layer to the support layer.
  • 15. A multi-layered wound dressing according to claim 1, further comprising a wound contact layer located adjacent the absorbent layer for positioning adjacent a wound.
  • 16. A multi-layered wound dressing according claim 15, further comprising a fluid transport layer between the wound contact layer and the absorbent layer for transporting exudate away from a wound into the absorbent layer.
  • 17. A method of treating a wound comprising placing a multi-layered wound dressing according to claim 1 over a wound.
  • 18. A method of manufacturing a multi-layered wound dressing, the method comprising: forming a support layer that comprises a net layer and a bonding layer by coextruding the net layer and the bonding layer;forming a fibrous absorbent layer for absorbing exudate from a wound site; andlaminating the support layer and the absorbent layer together to form the wound dressing by attaching the bonding layer to the absorbent layer;wherein the support layer is configured to reduce shrinkage of at least a portion of the multi-layered wound dressing, andwherein the support layer has a tensile strength from 0.05 to 0.06 Nm.
  • 19. A method according to claim 18, wherein the bonding layer is formed from a polymer with a first melting temperature and the net layer is formed from a material with a second melting temperature higher than the first melting temperature of the polymer of the bonding layer, and wherein laminating the support layer and the absorbent layer comprises laminating by using heat so that the net layer maintains its structure during application of heat.
  • 20. A method according to claim 18, further comprising heat laminating the support layer to fibres in the absorbent layer via the bonding layer, wherein the bonding layer comprises a low melting point ethylene-vinyl acetate adhesive, and wherein the support layer comprises a net formed from a material with a higher melting temperature than that of the bonding layer.
Priority Claims (1)
Number Date Country Kind
1618298 Oct 2016 GB national
PCT Information
Filing Document Filing Date Country Kind
PCT/EP2017/077154 10/24/2017 WO
Publishing Document Publishing Date Country Kind
WO2018/077872 5/3/2018 WO A
US Referenced Citations (572)
Number Name Date Kind
730062 Widmer Jun 1903 A
1052274 Purdy Feb 1913 A
2054768 Gale, Jr. et al. Sep 1936 A
2233209 Herzog Feb 1941 A
2280506 Betts Apr 1942 A
2682873 Idnis et al. Jul 1954 A
2905174 Smith Sep 1959 A
2992644 Plantinga et al. Jul 1961 A
3043301 Plantinga et al. Jul 1962 A
3156242 Crowe, Jr. et al. Nov 1964 A
3204277 Sierik et al. Sep 1965 A
3301429 McClain Jan 1967 A
3416524 Meier Dec 1968 A
3529597 Fuzak et al. Sep 1970 A
3616154 Dow et al. Oct 1971 A
3687136 Carmody Aug 1972 A
4212296 Schaar Jul 1980 A
4649909 Thompson Mar 1987 A
4798603 Meyer et al. Jan 1989 A
4834735 Alemany et al. May 1989 A
4846164 Martz Jul 1989 A
4901714 Jensen Feb 1990 A
4968181 Goldman Nov 1990 A
4973325 Sherrod et al. Nov 1990 A
4988344 Reising et al. Jan 1991 A
4988345 Reising Jan 1991 A
5018515 Gilman May 1991 A
5021050 Iskra Jun 1991 A
5037409 Chen et al. Aug 1991 A
5065600 Byles Nov 1991 A
5115801 Cartmell et al. May 1992 A
5124197 Bernardin et al. Jun 1992 A
5149334 Lahrman et al. Sep 1992 A
5151091 Glaug et al. Sep 1992 A
5160328 Cartmell et al. Nov 1992 A
5171391 Chmielewski et al. Dec 1992 A
5175046 Nguyen Dec 1992 A
5176663 Svedman et al. Jan 1993 A
5197945 Cole et al. Mar 1993 A
5217445 Young et al. Jun 1993 A
5236427 Hamajima et al. Aug 1993 A
5242435 Murji et al. Sep 1993 A
5257982 Cohen et al. Nov 1993 A
5271987 Iskra Dec 1993 A
5281208 Thompson et al. Jan 1994 A
5294478 Wanek et al. Mar 1994 A
5296290 Brassington Mar 1994 A
5314743 Meirowitz et al. May 1994 A
5318554 Young et al. Jun 1994 A
5330456 Robinson Jul 1994 A
5336219 Krantz Aug 1994 A
5342336 Meirowitz et al. Aug 1994 A
5348547 Payne et al. Sep 1994 A
5354261 Clark et al. Oct 1994 A
5356405 Thompson et al. Oct 1994 A
5360420 Cook et al. Nov 1994 A
5364381 Soga et al. Nov 1994 A
5364382 Latimer et al. Nov 1994 A
5366451 Levesque Nov 1994 A
5368909 Langdon et al. Nov 1994 A
5368926 Thompson et al. Nov 1994 A
5374260 Lemay et al. Dec 1994 A
5380294 Persson Jan 1995 A
5382245 Thompson et al. Jan 1995 A
5387208 Ashton et al. Feb 1995 A
5387209 Yamamoto et al. Feb 1995 A
5397316 LaVon et al. Mar 1995 A
5401267 Couture-Dorschner et al. Mar 1995 A
5425725 Tanzer et al. Jun 1995 A
5431643 Ouellette et al. Jul 1995 A
5437651 Todd et al. Aug 1995 A
5447492 Cartmell et al. Sep 1995 A
5454800 Hirt et al. Oct 1995 A
5456660 Reich et al. Oct 1995 A
5465735 Patel Nov 1995 A
5470326 Dabi et al. Nov 1995 A
H1511 Chappell et al. Dec 1995 H
5480377 Cartmell et al. Jan 1996 A
5486167 Dragoo et al. Jan 1996 A
5487736 Van Phan Jan 1996 A
5497788 Inman et al. Mar 1996 A
5500270 Langdon et al. Mar 1996 A
5505719 Cohen et al. Apr 1996 A
5509914 Osborn, III Apr 1996 A
5514120 Johnston et al. May 1996 A
5520629 Heinecke et al. May 1996 A
5525407 Yang Jun 1996 A
5536264 Hsueh et al. Jul 1996 A
5538500 Peterson Jul 1996 A
H1585 Ahr Aug 1996 H
5545155 Hseih et al. Aug 1996 A
5549584 Gross Aug 1996 A
5549589 Horney et al. Aug 1996 A
5562107 Lavender et al. Oct 1996 A
5562646 Goldman et al. Oct 1996 A
5562650 Everett et al. Oct 1996 A
5579765 Cox et al. Dec 1996 A
5591148 McFall et al. Jan 1997 A
5591149 Cree et al. Jan 1997 A
5593395 Martz Jan 1997 A
5603707 Trombetta et al. Feb 1997 A
5603946 Constantine Feb 1997 A
5609588 DiPalma et al. Mar 1997 A
5613960 Mizutani Mar 1997 A
5614283 Potnis et al. Mar 1997 A
5614295 Quincy, III et al. Mar 1997 A
5628736 Thompson May 1997 A
5632731 Patel May 1997 A
H1657 Hammons et al. Jun 1997 H
5634915 Osterdahl Jun 1997 A
5636643 Argenta et al. Jun 1997 A
5637080 Geng Jun 1997 A
5643238 Baker Jul 1997 A
5645081 Argenta et al. Jul 1997 A
5648142 Phillips Jul 1997 A
5649915 Chauvette et al. Jul 1997 A
5649916 DiPalma et al. Jul 1997 A
5662599 Reich et al. Sep 1997 A
5665082 Boulanger Sep 1997 A
5669895 Murakami et al. Sep 1997 A
5675079 Gilman et al. Oct 1997 A
5683354 Levy Nov 1997 A
5700254 McDowall et al. Dec 1997 A
5702356 Hathman Dec 1997 A
5704905 Jensen et al. Jan 1998 A
5713384 Roach et al. Feb 1998 A
5713842 Kay Feb 1998 A
5716703 Payne Feb 1998 A
5728084 Palumbo et al. Mar 1998 A
5728085 Widlund et al. Mar 1998 A
5733273 Ahr Mar 1998 A
5752945 Mosley et al. May 1998 A
5762641 Bewick-Sonntag et al. Jun 1998 A
5788684 Abuto et al. Aug 1998 A
5801107 Everhart et al. Sep 1998 A
5810798 Finch et al. Sep 1998 A
5817081 LaVon et al. Oct 1998 A
5820578 Johansen Oct 1998 A
5827213 Jensen Oct 1998 A
5827254 Trombetta et al. Oct 1998 A
5830202 Bogdanski et al. Nov 1998 A
5837627 Halabisky et al. Nov 1998 A
5840052 Johns Nov 1998 A
5843025 Shaari Dec 1998 A
5843064 Koczab Dec 1998 A
5855572 Schmidt Jan 1999 A
5865822 Hamajima et al. Feb 1999 A
5865824 Chen et al. Feb 1999 A
5873867 Coles et al. Feb 1999 A
5877097 West et al. Mar 1999 A
5891120 Chmielewski Apr 1999 A
5895379 Litchholt et al. Apr 1999 A
5897541 Uitenbroek et al. Apr 1999 A
5916507 Dabi et al. Jun 1999 A
5925026 Arteman et al. Jul 1999 A
5931823 Stokes et al. Aug 1999 A
5938995 Koltisko, Jr. et al. Aug 1999 A
5941863 Guidotti et al. Aug 1999 A
5947945 Cree et al. Sep 1999 A
5951535 Fujiwara et al. Sep 1999 A
5961506 Guidotti et al. Oct 1999 A
5968027 Cole et al. Oct 1999 A
5989478 Ouellette et al. Nov 1999 A
6022610 Phan et al. Feb 2000 A
6037518 Guidotti et al. Mar 2000 A
6040493 Cooke et al. Mar 2000 A
6060638 Paul et al. May 2000 A
6068620 Chmielewski May 2000 A
6071267 Zamierowski Jun 2000 A
6075177 Bahia et al. Jun 2000 A
6077526 Scully et al. Jun 2000 A
6096015 Yeo et al. Aug 2000 A
6103953 Cree et al. Aug 2000 A
6103954 Grondin et al. Aug 2000 A
6107539 Palumbo et al. Aug 2000 A
6124520 Roberts Sep 2000 A
6124521 Roberts Sep 2000 A
6127595 Makoui et al. Oct 2000 A
6142982 Hunt et al. Nov 2000 A
6168849 Braverman et al. Jan 2001 B1
6191340 Carlucci et al. Feb 2001 B1
6206865 Chen et al. Mar 2001 B1
6223383 Vanputten May 2001 B1
6235966 Magnusson et al. May 2001 B1
6264776 DiPalma Jul 2001 B1
6294710 Schmidt et al. Sep 2001 B1
6297423 Schoenfeldt et al. Oct 2001 B1
6344036 Ivansson Feb 2002 B1
6345623 Heaton et al. Feb 2002 B1
6362390 Carlucci et al. Mar 2002 B1
6369292 Strack et al. Apr 2002 B1
6372952 Lash et al. Apr 2002 B1
6403857 Gross et al. Jun 2002 B1
6468295 Augustine et al. Oct 2002 B2
6497689 Schmidt et al. Dec 2002 B1
6506175 Goldstein Jan 2003 B1
6506960 Young et al. Jan 2003 B1
6521813 Chihani Feb 2003 B1
6528696 Ireland Mar 2003 B1
6534149 Daley et al. Mar 2003 B1
6545194 Schmidt et al. Apr 2003 B1
6551295 Schmidt et al. Apr 2003 B1
6570057 Schmidt et al. May 2003 B1
6570058 Fuchs et al. May 2003 B1
6573424 Raidel et al. Jun 2003 B1
6586653 Graeme, III et al. Jul 2003 B2
6610898 Magnusson et al. Aug 2003 B1
6610903 Latimer et al. Aug 2003 B1
6613028 Daley et al. Sep 2003 B1
6613953 Altura Sep 2003 B1
6613955 Lindsay et al. Sep 2003 B1
6626891 Ohmstede Sep 2003 B2
6630611 Malowaniec Oct 2003 B1
6648862 Watson Nov 2003 B2
6664439 Arndt et al. Dec 2003 B1
6683229 Ehrnsperger et al. Jan 2004 B1
6685681 Lockwood et al. Feb 2004 B2
6706940 Worthley Mar 2004 B2
6719742 McCormack et al. Apr 2004 B1
6727403 Ehrnsperger et al. Apr 2004 B1
6752794 Lockwood et al. Jun 2004 B2
6762337 Boukanov et al. Jul 2004 B2
6764459 Donaldson Jul 2004 B1
6776769 Smith Aug 2004 B2
6783837 Creagan et al. Aug 2004 B1
6787682 Gilman Sep 2004 B2
6835192 Guidotti et al. Dec 2004 B1
6838589 Liedtke et al. Jan 2005 B2
6841715 Roberts Jan 2005 B2
6878647 Rezai Apr 2005 B1
6936037 Bubb et al. Aug 2005 B2
6951553 Bubb et al. Oct 2005 B2
6960181 Stevens Nov 2005 B2
6998511 Worthley Feb 2006 B2
7004915 Boynton et al. Feb 2006 B2
7049478 Smith May 2006 B1
7108683 Zamierowski Sep 2006 B2
7112712 Ancell Sep 2006 B1
7118545 Boyde Oct 2006 B2
7122023 Hinoki Oct 2006 B1
7122712 Lutri et al. Oct 2006 B2
7183345 Kim Feb 2007 B2
7195624 Lockwood et al. Mar 2007 B2
7294751 Propp et al. Nov 2007 B2
7294752 Propp Nov 2007 B1
7381859 Hunt et al. Jun 2008 B2
7429689 Chen et al. Sep 2008 B2
7438705 Karpowicz et al. Oct 2008 B2
7476205 Erdmann Jan 2009 B2
7507870 Nielsen et al. Mar 2009 B2
7511187 Kelly Mar 2009 B2
7563940 Kurata Jul 2009 B2
7569742 Haggstrom et al. Aug 2009 B2
7576256 Bjornberg et al. Aug 2009 B2
7605298 Bechert et al. Oct 2009 B2
7615036 Joshi et al. Nov 2009 B2
7622629 Aali Nov 2009 B2
7645269 Zamierowski Jan 2010 B2
7676257 Suryanarayanan et al. Mar 2010 B2
7708724 Weston May 2010 B2
7722582 Lina et al. May 2010 B2
7723561 Propp May 2010 B2
7749531 Booher Jul 2010 B2
7759537 Bishop et al. Jul 2010 B2
7759539 Shaw et al. Jul 2010 B2
7775998 Riesinger Aug 2010 B2
7776028 Miller et al. Aug 2010 B2
7779625 Joshi et al. Aug 2010 B2
7794438 Henley et al. Sep 2010 B2
7838719 Hilton, Jr. Nov 2010 B2
7838723 Schmidt et al. Nov 2010 B1
7909805 Weston Mar 2011 B2
7922703 Riesinger Apr 2011 B2
7935066 Shives et al. May 2011 B2
7959624 Riesinger Jun 2011 B2
7964766 Blott et al. Jun 2011 B2
7976519 Bubb et al. Jul 2011 B2
7988673 Wright et al. Aug 2011 B2
8021347 Vitaris et al. Sep 2011 B2
8062272 Weston Nov 2011 B2
8092436 Christensen Jan 2012 B2
8147468 Barta et al. Apr 2012 B2
8152785 Vitaris Apr 2012 B2
8162907 Heagle Apr 2012 B2
8168848 Lockwood et al. May 2012 B2
8188331 Barta et al. May 2012 B2
8202261 Kazala, Jr. et al. Jun 2012 B2
8212101 Propp Jul 2012 B2
8241261 Randolph et al. Aug 2012 B2
8246606 Stevenson et al. Aug 2012 B2
8252971 Aali et al. Aug 2012 B2
8314283 Kingsford et al. Nov 2012 B2
8328858 Barsky et al. Dec 2012 B2
8372050 Jaeb et al. Feb 2013 B2
8376972 Fleischmann Feb 2013 B2
8382731 Johannison Feb 2013 B2
8403899 Sherman Mar 2013 B2
8404921 Lee et al. Mar 2013 B2
8425478 Olson Apr 2013 B2
8444611 Wilkes et al. May 2013 B2
8449508 Coulthard et al. May 2013 B2
8481804 Timothy Jul 2013 B2
8513481 Gergely et al. Aug 2013 B2
8535296 Blott et al. Sep 2013 B2
8545466 Andresen et al. Oct 2013 B2
8663198 Buan et al. Mar 2014 B2
8680360 Greener et al. Mar 2014 B2
8708998 Weston et al. Apr 2014 B2
8715256 Greener May 2014 B2
8722961 Vinton et al. May 2014 B2
8764732 Hartwell Jul 2014 B2
8791316 Greener Jul 2014 B2
8795247 Bennett et al. Aug 2014 B2
8801685 Armstrong et al. Aug 2014 B2
8814842 Coulthard et al. Aug 2014 B2
8843327 Vernon-Harcourt et al. Sep 2014 B2
8916742 Smith Dec 2014 B2
8986270 Johannison et al. Mar 2015 B2
9033942 Vess May 2015 B2
9061095 Adie et al. Jun 2015 B2
9220822 Hartwell Dec 2015 B2
9254353 Locke et al. Feb 2016 B2
9265665 Robinson et al. Feb 2016 B2
9579411 Addison et al. Feb 2017 B2
20010000795 Bolian, II et al. May 2001 A1
20010016985 Insley et al. Aug 2001 A1
20010018308 Quick et al. Aug 2001 A1
20010027302 Glaug et al. Oct 2001 A1
20010027305 Raidel et al. Oct 2001 A1
20010044610 Kim et al. Nov 2001 A1
20010051178 Blatchford et al. Dec 2001 A1
20010053904 Abuto Dec 2001 A1
20020007167 Dan et al. Jan 2002 A1
20020007169 Graef et al. Jan 2002 A1
20020019602 Geng Feb 2002 A1
20020019614 Woon et al. Feb 2002 A1
20020026166 Graef et al. Feb 2002 A1
20020034914 De Leon et al. Mar 2002 A1
20020035354 Mirle et al. Mar 2002 A1
20020062113 Thomas et al. May 2002 A1
20020064639 Rearick et al. May 2002 A1
20020087136 Widlund Jul 2002 A1
20020090511 Smith et al. Jul 2002 A1
20020110672 Muratore-Pallatino et al. Aug 2002 A1
20020123728 Graef et al. Sep 2002 A1
20020133132 Copat et al. Sep 2002 A1
20020150678 Cramer et al. Oct 2002 A1
20020165509 Baer et al. Nov 2002 A1
20020176964 Koslow Nov 2002 A1
20020177831 Daley et al. Nov 2002 A1
20020180092 Abba et al. Dec 2002 A1
20020183704 Fields et al. Dec 2002 A1
20030009122 Veras Jan 2003 A1
20030045707 West et al. Mar 2003 A1
20030045825 Etheredge, III Mar 2003 A1
20030050617 Chen et al. Mar 2003 A1
20030069563 Johnson Apr 2003 A1
20030070780 Chen et al. Apr 2003 A1
20030073967 Wahlstrom et al. Apr 2003 A1
20030088229 Baker et al. May 2003 A1
20030088231 Yoshimasa et al. May 2003 A1
20030093044 Wahlstrom et al. May 2003 A1
20030097101 Schmidt et al. May 2003 A1
20030097105 Chen et al. May 2003 A1
20030097113 Molee May 2003 A1
20030105442 Johnston et al. Jun 2003 A1
20030114816 Underhill et al. Jun 2003 A1
20030114818 Benecke et al. Jun 2003 A1
20030114821 Underhill et al. Jun 2003 A1
20030120249 Wulz et al. Jun 2003 A1
20030121588 Pargass et al. Jul 2003 A1
20030124311 Cree et al. Jul 2003 A1
20030134559 Delzer et al. Jul 2003 A1
20030135174 Benecke et al. Jul 2003 A1
20030135177 Baker Jul 2003 A1
20030150551 Baker Aug 2003 A1
20030157857 Cook et al. Aug 2003 A1
20030171729 Kaun et al. Sep 2003 A1
20030180341 Gooch et al. Sep 2003 A1
20030190854 Stagray Oct 2003 A1
20030199800 Levin Oct 2003 A1
20030208175 Gross et al. Nov 2003 A1
20030212359 Butler Nov 2003 A1
20030225383 Glaug et al. Dec 2003 A1
20040019338 Litvay et al. Jan 2004 A1
20040019339 Ranganathan et al. Jan 2004 A1
20040019340 McBride Jan 2004 A1
20040019342 Nagasuna et al. Jan 2004 A1
20040024102 Hayes Feb 2004 A1
20040024375 Litvay Feb 2004 A1
20040033750 Everett et al. Feb 2004 A1
20040049146 Kolte et al. Mar 2004 A1
20040054343 Barnett et al. Mar 2004 A1
20040054344 Roettger et al. Mar 2004 A1
20040065420 Graef et al. Apr 2004 A1
20040076662 Riesinger Apr 2004 A1
20040078016 Baker Apr 2004 A1
20040087927 Suzuki May 2004 A1
20040111074 Eliasson Jun 2004 A1
20040138602 Rossen Jul 2004 A1
20040177935 Hamed et al. Sep 2004 A1
20040181199 Moberg-Alehammar et al. Sep 2004 A1
20040204696 Chen Oct 2004 A1
20040230173 Barge et al. Nov 2004 A1
20040230184 Babusik et al. Nov 2004 A1
20040241214 Kirkwood et al. Dec 2004 A1
20040243042 Lipman Dec 2004 A1
20040243080 Baer Dec 2004 A1
20040243081 Suzuki et al. Dec 2004 A1
20040253894 Fell et al. Dec 2004 A1
20040254552 Mangold Dec 2004 A1
20050008825 Casey et al. Jan 2005 A1
20050013992 Azad et al. Jan 2005 A1
20050015036 Lutri et al. Jan 2005 A1
20050049566 Vukos et al. Mar 2005 A1
20050079361 Hamed et al. Apr 2005 A1
20050096616 Arora et al. May 2005 A1
20050112979 Sawyer et al. May 2005 A1
20050119631 Giloh et al. Jun 2005 A1
20050136773 Yahiaoui et al. Jun 2005 A1
20050165371 Giacometti Jul 2005 A1
20050215965 Schmidt et al. Sep 2005 A1
20050215967 Toro et al. Sep 2005 A1
20050222547 Beruda et al. Oct 2005 A1
20050228353 Thomas Oct 2005 A1
20050261649 Cohen Nov 2005 A1
20050267429 Cohen Dec 2005 A1
20060003604 Angerpointner Jan 2006 A1
20060009744 Erdman et al. Jan 2006 A1
20060020250 Chester et al. Jan 2006 A1
20060058750 Di Girolamo et al. Mar 2006 A1
20060069366 Cole Mar 2006 A1
20060069367 Waksmundzki et al. Mar 2006 A1
20060069375 Waksmundzki et al. Mar 2006 A1
20060122548 Abrams Jun 2006 A1
20060122572 Suarez Jun 2006 A1
20060153904 Smith et al. Jul 2006 A1
20060161122 Erdman et al. Jul 2006 A1
20060178650 Hakansson et al. Aug 2006 A1
20060184147 Hamed Aug 2006 A1
20060206047 Lampe et al. Sep 2006 A1
20060206073 Crane et al. Sep 2006 A1
20060206074 Bernal et al. Sep 2006 A1
20060241542 Gudnason et al. Oct 2006 A1
20060282028 Howard et al. Dec 2006 A1
20070003604 Jones Jan 2007 A1
20070021697 Ginther et al. Jan 2007 A1
20070073254 Ponomarenko et al. Mar 2007 A1
20070078467 Mullen Apr 2007 A1
20070100308 Miyairi May 2007 A1
20070142804 Bernard Jun 2007 A1
20070167096 Scott Jul 2007 A1
20070167884 Mangrum et al. Jul 2007 A1
20070224903 Chakravarty et al. Sep 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070254550 Hamed et al. Nov 2007 A1
20070270070 Hamed Nov 2007 A1
20070282236 LaGreca Dec 2007 A1
20080004581 Babusik et al. Jan 2008 A1
20080015532 Waksmundzki Jan 2008 A1
20080058691 Sorensen Mar 2008 A1
20080082075 Morrell-Schwartz Apr 2008 A1
20080090050 Seyler et al. Apr 2008 A1
20080091152 Asherman Apr 2008 A1
20080114317 Seyler May 2008 A1
20080119586 Byerly et al. May 2008 A1
20080147024 Potts et al. Jun 2008 A1
20080167592 Greer Jul 2008 A1
20080243100 Wu et al. Oct 2008 A1
20080254103 Harris et al. Oct 2008 A1
20080255533 Wu et al. Oct 2008 A1
20080275409 Kane et al. Nov 2008 A1
20080312621 Hundorf et al. Dec 2008 A1
20080312622 Hundorf et al. Dec 2008 A1
20090062760 Wright et al. Mar 2009 A1
20090065014 Nagata Mar 2009 A1
20090076472 Goldwasser et al. Mar 2009 A1
20090112175 Bissah et al. Apr 2009 A1
20090204087 Herfert et al. Aug 2009 A1
20090216168 Eckstein Aug 2009 A1
20090227935 Zanella et al. Sep 2009 A1
20090227969 Jaeb et al. Sep 2009 A1
20090240218 Braga et al. Sep 2009 A1
20090281471 Iwahashi et al. Nov 2009 A1
20090293887 Wilkes et al. Dec 2009 A1
20090299251 Buan Dec 2009 A1
20090299255 Kazala, Jr. et al. Dec 2009 A1
20090299340 Kazala, Jr. et al. Dec 2009 A1
20100010461 Herfert et al. Jan 2010 A1
20100030171 Canada et al. Feb 2010 A1
20100036334 Heagle et al. Feb 2010 A1
20100036342 Carlucci et al. Feb 2010 A1
20100048072 Kauschke et al. Feb 2010 A1
20100055158 Vitaris et al. Mar 2010 A1
20100069858 Olson Mar 2010 A1
20100084074 McClernon et al. Apr 2010 A1
20100087767 McNeil Apr 2010 A1
20100106120 Holm Apr 2010 A1
20100106121 Holm Apr 2010 A1
20100121286 Locke et al. May 2010 A1
20100121298 Seyler et al. May 2010 A1
20100122417 Vrzalik et al. May 2010 A1
20100125234 Smith May 2010 A1
20100125258 Coulthard et al. May 2010 A1
20100168695 Robles et al. Jul 2010 A1
20100179463 Greener et al. Jul 2010 A1
20100217177 Cali et al. Aug 2010 A1
20100256545 Aali et al. Oct 2010 A1
20100256584 Litvay Oct 2010 A1
20100256586 Bergstrom et al. Oct 2010 A1
20100262091 Larsson Oct 2010 A1
20100305526 Robinson et al. Dec 2010 A1
20100318047 Ducker et al. Dec 2010 A1
20100318052 Ha et al. Dec 2010 A1
20100324516 Braga et al. Dec 2010 A1
20110004172 Eckstein et al. Jan 2011 A1
20110052664 Tennican et al. Mar 2011 A1
20110054422 Locke et al. Mar 2011 A1
20110059329 Dobrawa et al. Mar 2011 A1
20110060303 Bissah et al. Mar 2011 A1
20110092927 Wilkes et al. Apr 2011 A1
20110098621 Fabo et al. Apr 2011 A1
20110106030 Scholz May 2011 A1
20110112492 Bharti et al. May 2011 A1
20110125119 Weismantel et al. May 2011 A1
20110137222 Masini Jun 2011 A1
20110152813 Ellingson Jun 2011 A1
20110178375 Forster Jul 2011 A1
20110183109 Seyler et al. Jul 2011 A1
20110184364 Biggs et al. Jul 2011 A1
20110184370 Seyler et al. Jul 2011 A1
20110208145 Zhang et al. Aug 2011 A1
20110213286 Riesinger Sep 2011 A1
20110218509 Dontas Sep 2011 A1
20110223413 Herfert et al. Sep 2011 A1
20110224631 Simmons et al. Sep 2011 A1
20110238026 Zhang et al. Sep 2011 A1
20110245788 Marquez Canada Oct 2011 A1
20110247636 Pollack Oct 2011 A1
20110257572 Locke et al. Oct 2011 A1
20110268932 Catalan et al. Nov 2011 A1
20120004632 Zhang et al. Jan 2012 A1
20120045639 Whitmore et al. Feb 2012 A1
20120053547 Schroeder et al. Mar 2012 A1
20120071848 Zhang et al. Mar 2012 A1
20120095426 Visscher et al. Apr 2012 A1
20120101465 McGuire, Jr. Apr 2012 A1
20120123311 Weidemann-Hendrickson et al. May 2012 A1
20120130332 Cotton et al. May 2012 A1
20120136329 Carney May 2012 A1
20120143158 Yang et al. Jun 2012 A1
20120172778 Rastegar et al. Jul 2012 A1
20120197229 Buan et al. Aug 2012 A1
20120203145 Nilsson Aug 2012 A1
20120220968 Confalone et al. Aug 2012 A1
20120232502 Lowing Sep 2012 A1
20120238932 Atteia et al. Sep 2012 A1
20120283529 Marchand et al. Nov 2012 A1
20120302440 Theliander et al. Nov 2012 A1
20120308780 Rottger et al. Dec 2012 A1
20120310186 Moghe et al. Dec 2012 A1
20120310197 Thomas Dec 2012 A1
20120330252 Stokes et al. Dec 2012 A1
20120330253 Robinson et al. Dec 2012 A1
20130012902 Rovaniemi Jan 2013 A1
20130197460 Shaw Aug 2013 A1
20140114268 Auguste et al. Apr 2014 A1
20150159066 Hartwell et al. Jun 2015 A1
20150174304 Askem et al. Jun 2015 A1
20180125720 Pigg May 2018 A1
20190110932 Mumby et al. Apr 2019 A1
20190216651 Vitaris et al. Jul 2019 A1
Foreign Referenced Citations (109)
Number Date Country
101002707 Jul 2007 CN
0053936 Jun 1982 EP
0147119 Jul 1985 EP
0541251 May 1993 EP
0619105 Oct 1994 EP
0748894 Dec 1996 EP
0875224 Nov 1998 EP
0941726 Sep 1999 EP
1013290 Jun 2000 EP
1048278 Nov 2000 EP
1066809 Jan 2001 EP
1312328 May 2003 EP
1452156 Sep 2004 EP
1 314 410 Feb 2010 EP
2161011 Mar 2010 EP
2366721 Sep 2011 EP
2659915 Oct 2015 EP
2272917 Jun 1994 GB
2355228 Apr 2001 GB
2435422 Aug 2007 GB
2435423 Aug 2007 GB
2489947 Oct 2012 GB
2525494 Oct 2015 GB
2001145655 May 2001 JP
2007275185 Oct 2007 JP
2008119497 May 2008 JP
WO-9111161 Aug 1991 WO
WO-9111162 Aug 1991 WO
WO-9301778 Feb 1993 WO
WO-9301781 Feb 1993 WO
WO-9311726 Jun 1993 WO
WO-9513042 May 1995 WO
WO-9513779 May 1995 WO
WO-9514451 Jun 1995 WO
WO-9516424 Jun 1995 WO
WO-9607783 Mar 1996 WO
WO-9621410 Jul 1996 WO
WO-9711658 Apr 1997 WO
WO-9714384 Apr 1997 WO
WO-9820916 May 1998 WO
WO-9822279 May 1998 WO
WO-9904830 Feb 1999 WO
WO-9939671 Aug 1999 WO
WO-9945876 Sep 1999 WO
WO-9945878 Sep 1999 WO
WO-9956687 Nov 1999 WO
WO-0000016 Jan 2000 WO
WO-0000127 Jan 2000 WO
WO-0000129 Jan 2000 WO
WO-0000130 Jan 2000 WO
WO-0000131 Jan 2000 WO
WO-0040190 Jul 2000 WO
WO-0042957 Jul 2000 WO
WO-0059438 Oct 2000 WO
WO-0172251 Oct 2001 WO
WO-0190465 Nov 2001 WO
WO-0217840 Mar 2002 WO
WO-0224132 Mar 2002 WO
WO-0226180 Apr 2002 WO
WO-0238096 May 2002 WO
WO-02076379 Oct 2002 WO
WO-03057307 Jul 2003 WO
WO-03073971 Sep 2003 WO
WO-2004043321 May 2004 WO
WO-2004073566 Sep 2004 WO
WO-2004098474 Nov 2004 WO
WO-2006105305 Oct 2006 WO
WO-2007035038 Mar 2007 WO
WO-2007040606 Apr 2007 WO
WO-2007077214 Jul 2007 WO
WO-2007077216 Jul 2007 WO
WO-2007082538 Jul 2007 WO
WO-2007116347 Oct 2007 WO
WO-2007134516 Nov 2007 WO
WO-2008049277 May 2008 WO
WO-2008131895 Nov 2008 WO
WO-2009019227 Feb 2009 WO
WO-2009019229 Feb 2009 WO
WO-2009103031 Aug 2009 WO
WO-2009152021 Dec 2009 WO
WO-2010032951 Mar 2010 WO
WO-2010072395 Jul 2010 WO
WO-2010082872 Jul 2010 WO
WO-2010089448 Aug 2010 WO
WO-2010139926 Dec 2010 WO
WO-2011019476 Feb 2011 WO
WO-2011023275 Mar 2011 WO
WO-2011023650 Mar 2011 WO
WO 2011057240 May 2011 WO
WO-2011058311 May 2011 WO
WO-2011063818 Jun 2011 WO
WO-2011113728 Sep 2011 WO
WO-2011128651 Oct 2011 WO
WO-2011152368 Dec 2011 WO
WO-2012009370 Jan 2012 WO
WO-2012035787 Mar 2012 WO
WO-2012074512 Jun 2012 WO
WO-2012146656 Nov 2012 WO
WO-2012150235 Nov 2012 WO
WO-2012168298 Dec 2012 WO
WO-2013014317 Jan 2013 WO
WO-2013029652 Mar 2013 WO
WO-2013060732 May 2013 WO
WO-2013175306 Nov 2013 WO
WO-2014003957 Jan 2014 WO
WO 2017174332 Oct 2017 WO
WO 2018077872 May 2018 WO
WO-2019020550 Jan 2019 WO
9605526 Feb 1997 ZA
Non-Patent Literature Citations (13)
Entry
Brief Communication—Letter from the Proprietor of the Patent dated Jun. 16, 2020, for the Opposition of European Patent No. EP2731564, 19 pages.
International Preliminary Report on Patentability for Application No. PCT/EP2017/077154, dated May 9, 2019, 8 pages.
International Preliminary Report on Patentability for Application No. PCT/GB2012/000587, dated Jan. 23, 2014, 12 pages.
International Search Report and Written Opinion for Application No. PCT/GB2012/000587, dated Oct. 8, 2013, 17 pages.
KCI Licensing Inc, “Prevena™ Incision Management System—Clinician Guide—Instructions for Use,” 390061 Rev D, Jan. 2010, 10 pages.
KCI Licensing Inc, “Prevena™ Incision Management System—Clinician Guide—Instructions for Use,” 390153-WEB Rev B, Jan. 2010, 12 pages.
KCI Licensing, “Prevena™ Incision Management System—Patient Guide”, 390064 Rev D, Jan. 2010, 4 pages.
KCI Licensing, “Prevena™ Incision Management System—Patient Guide,” 390152-WEB C, Jan. 2011, 6 pages.
KCI Licensing, Prevena™ Incision Management System, Jun. 22, 2010, in 2 pages.
Notice of Opposition—Statement of Facts and Evidence for the European Patent No. 2731564, mailed Jan. 22, 2020, 12 pages.
Smith & Nephew, Allevyn Gentle Border Multisite, Jun. 2011, 2 pages.
Smith and Nephew Inc., “Allevyn Wound Dressings Pamphlet,” 2008, 2 pages.
International Search Report and Written Opinion, re PCT Application No. PCT/EP2017/077154, dated Dec. 1, 2017.
Related Publications (1)
Number Date Country
20190274889 A1 Sep 2019 US